ID Week Commentary | Dr. Junyan Qu: Real-world Efficacy Comparison of CT vs. CZA in Treating MDR-PA Infections

ID Week Commentary | Dr. Junyan Qu: Real-world Efficacy Comparison of CT vs. CZA in Treating MDR-PA Infections

Multi-drug resistant organisms (MDRO) are commonly found in bacteria such as Enterobacteriaceae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia. In recent years, the emergence and spread of MDRO have posed numerous challenges in clinical practice, with limited treatment options being one of the thorny issues. Beta-lactamase inhibitor combinations are essential in the clinical management of MDRO infections, among which Ceftolozane-Tazobactam (CT) and Ceftazidime-Avibactam (CZA) are frontline drugs for treating Multi-drug Resistant Pseudomonas aeruginosa (MDR-PA) infections. However, there is a lack of sufficient research data comparing the efficacy of these two drugs. At the recent IDWeek 2023 held in the United States, researchers presented a multicenter observational study (Abstract No: 1109) that compared the efficacy of CT and CZA in treating MDR-PA-induced bacteremia or pneumonia. " Infectious Disease Frontline" invited Dr. Junyan Qu, from West China Hospital of Sichuan University, to introduce and comment on this study.
ESMO ASIA 2023 opens, and CSCO accepts certificate of appreciation

ESMO ASIA 2023 opens, and CSCO accepts certificate of appreciation

ESMO ASIA 2023 inaugurated its opening session, heralding a landmark event in the world of oncology. Hosted in the prestigious Hall 406, this congress brings together the brightest minds in cancer research and treatment, uniting a global community in the fight against this challenging disease. The opening ceremony featured the traditional Dragon Dance, symbolizing prosperity and health. This cultural performance underscored the congress's commitment to diversity and inclusivity, setting a vibrant tone for the event. After the opening address, ESMO also commended society in Asia for their outstanding contributions in promoting international cooperation and exchanges. Dr. Donglu Zhao accepted the certificate of appreciation on behalf of the Chinese Society of Clinical Oncology (CSCO).
ESMO Expert Commentary | Professor Yao Zhu: Success or Failure Does Not Define a Hero, Numerous Prostate Cancer Studies Aid in Optimizing Patient Survival

ESMO Expert Commentary | Professor Yao Zhu: Success or Failure Does Not Define a Hero, Numerous Prostate Cancer Studies Aid in Optimizing Patient Survival

Prostate cancer is the leading male urological tumor in China and has become one of the fastest-growing male malignancies in the past decade. The recent ESMO conference unveiled several advancements in prostate cancer research, extending the survival prospects for patients. Although there were some negative results, the research still holds positive significance. "Oncology Frontier" has specially invited Professor Yao Zhu from Fudan University's affiliated Cancer Hospital to provide an in-depth interpretation of these research developments.
APASL 2023 | Professor Li Jun: Latest Developments in ACLF Early Warning Models, Pioneering with Large-Scale Data from China

APASL 2023 | Professor Li Jun: Latest Developments in ACLF Early Warning Models, Pioneering with Large-Scale Data from China

Acute-on-Chronic Liver Failure (ACLF) is a complex syndrome characterized by acute deterioration of liver function on the background of chronic liver disease, accompanied by liver and/or extrahepatic organ failure. It poses a significant challenge in internal medicine due to its high short-term mortality rate of 50% to 90%. Early prediction of the risk of ACLF in patients and advancing the treatment window can effectively improve patient outcomes.